Anthony R. Ball

Executive Operator | Founder | Scientific Director

With over 15 years of rigorous R&D experience, I am an executive operator and founder dedicated to bridging the gap between advanced scientific discovery and commercial viability. My career is defined by the ability to seamlessly translate complex, deep-tech biology and engineering innovations into market-ready platforms. Whether directing multi-million dollar federal pipelines, leading cross-functional teams, or navigating stringent regulatory landscapes, I engineer strategic solutions that scale hard science into high-impact enterprises.

Executive Leadership & Core Competencies

Cross-functional Team Leadership (Engineering & Biology) Multimillion-Dollar R&D Pipeline Management Regulatory Strategy (FDA 510(k), GLP/GMP) Capital Raising & Federal Procurement DoD/SBIR Contract Acquisition Deep-Tech Commercialization Corporate Strategy & Scaling Operations Intellectual Property & Patent Acquisition

Scale & Capital Metrics

$13M+

Total Capital & Grants Raised

DoD / Army

XTechSearch Biodefense Contracts

15+ Years

R&D & C-Level Experience

Executive Resume & Discussion

For board, founder, life-science leadership, business development, and executive director conversations, I maintain role-specific executive resume packages rather than a single generic document. A public executive resume is available below, and I can provide a more targeted version for a specific opportunity.

Executive Roles & Multi-Industry Impact

Tap or hover over each venture to see the operating thesis, concrete accomplishments, and executive capabilities demonstrated.

Tap or hover over an individual company to see the accomplishments and executive capabilities demonstrated there.

Founder / Venture Operating Portfolio

This portfolio is not a generic “entrepreneurship” claim. It is a record of founder-level execution across grant-funded medical-device R&D, regulatory-scientific consulting, laboratory and engineering infrastructure, investor/partner materials, and early-stage venture operations.

GAMA Therapeutics

Photomedicine and infection-control venture. CSO / co-founder / board voting member. Pitch materials documented a Mansfield BioIncubator BSL-2 lab, a 5 full-time / 4 part-time operating team, $1.8M seed/grant funding, and $20M+ in grant opportunities under review or in progress. Led proposal generation, prototype strategy, contractor coordination, patent support, and publication planning for LED-based catheter/device disinfection and wound-care platforms.

UV Light Care

Healthcare safety venture focused on UV/light-based infection control. Built M2D2-facing materials around catheter-associated infection burden, CLABSI/MRSA problem framing, germicidal UV catheter-lumen disinfection, portability, and low-training use. Translated photobiology, biofilm science, and optical-test-bed concepts into an early device-development pathway.

Gliese 623B

Research consultancy and venture vehicle supporting sponsored research, UMass Lowell M2D2 collaboration, biofilm methods, optics, contract-research proposals, and stakeholder communication. Evidence includes catheter-segment biofilm-apparatus planning, continuous-flow reactor concepts, peristaltic-pump / bubble-trap / luer-component selection, UV-transparent materials review, and cost-saving laboratory redesign.

GROW-RI

Agritech / controlled-environment agriculture venture tied to UV/visible-light crop sanitation, photobiomodulation, fungal/pathogen reduction, software-controlled LED growth and pest-control panels, facility automation, crop monitoring, data analytics, and robotic-harvesting concepts. Public coverage by VerticalFarmDaily identified Tony as CSO and described GROW-RI’s GENESIS automation systems for greenhouses and indoor farms. Internal evidence materials frame a $3M funding plan for a Warwick, Rhode Island plant-pathology lab, prototyping, staffing, market research, licensing, and IP strategy.

BioCellR8

Scientific, regulatory, and commercialization consulting platform spanning nutraceuticals, cosmetics, cannabis/CBD claims risk, export frameworks, commercialization plans, joint-venture documentation, BSL-2 compliance frameworks, and emerging-client technical strategy. Evidence includes MoCRA / FD&C / FDA / FTC claim-risk analysis, ISO 22716 quality-system planning, safety substantiation, vendor/SOP review, and JV/IP structure review.

Venture Infrastructure

Built and operated research infrastructure including BSL-2 and engineering-lab environments; generated scopes of work, budgets, proposals, critical-path plans, vendor/CRO coordination, IP narratives, and investor / board-facing executive materials.

Available Executive Support

Founder / fractional executive support Technology commercialization strategy Proposal, protocol, and scope-of-work generation Research-team assembly and advisory-board planning Investor and board-facing materials Scientific business development and partner mapping Patent / IP landscape support Startup operating models and gated milestones BSL-2 / regulated research facility planning CRO, vendor, and academic interface management

Scientific & Technical Pedigree

Extensive experience ensuring adherence to federal and international scientific standards.

Served as Study Director for FDA 510(k) clearances.
Managed and directed extensive GLP (Good Laboratory Practice) and GMP (Good Manufacturing Practice) compliant studies.
Ensured rigorous scientific backbone for C-suite decision-making and product pipelines.

Proven track record of defining, securing, and commercializing proprietary technology.

Successfully acquired 3 USPTO Patents outlining novel scientific hardware and biological methodologies.
Drafted and executed robust IP strategies to protect deep-tech assets against market competition.

Respected foundational research within the scientific community.

Authored highly-cited academic manuscripts across top-tier peer-reviewed journals.
Maintained active engagements and collaborative data analysis for ongoing manuscript preparations.

"True innovation occurs when the unyielding rigor of the scientific method is married to the relentless execution of business strategy. We do not just build technology; we engineer solutions that survive contact with the real world."